Rick Bienkowski
Stock Analyst at Cantor Fitzgerald
(0)
# 4893
Out of 5,255 analysts
37
Total ratings
19.35%
Success rate
-31.30%
Average return
Main Sectors:
Top Industries:
| Name | Action | Price Target | Current | % Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
VERV Verve Therapeutics | Upgrades: Overweight | n/a | n/a | n/a | 4 | Apr 15, 2025 | |
BEAM Beam Therapeutics | Reiterates: Overweight | n/a | n/a | n/a | 12 | Mar 12, 2025 | |
LEGN Legend Biotech | Reiterates: Overweight | 83 83 | 34.28 | 142.12% | 2 | Dec 9, 2024 | |
ACLX Arcellx | Initiates Coverage On: Overweight | n/a | n/a | n/a | 1 | Sep 3, 2024 | |
NTLA Intellia Therapeutic... | Reiterates: Overweight | 65 65 | 8.29 | 684.08% | 7 | Jun 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Neutral | n/a | n/a | n/a | 1 | Nov 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Overweight | 14 | 1.53 | 815.03% | 6 | Sep 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Outperform | 112 107 | 38.31 | 179.3% | 4 | Aug 8, 2022 |